RPS6KA3 and melanoma: In line with these results, we observed enhanced phosphorylation of the RSK target YB-1 in mitotic vemurafenib resistant melanoma cells as well as elevated RSK activation upon M-phase arrest, suggesting a general role of RSK in mitosis throughout different cell types.